Genmab — December 2018
-
Genmab har især vist styrke under den seneste tids store fald på markederne. A/B har været største køber de fleste dage efterfulgt af ENS. Det er meget betryggende.
-
Det samme har Novo også gjort. Aktien er kun1,91% nede i de seneste tre måneder. Dog er det minus 11% for hele 2018.
-
-
God morgen.
-
-
-
God morgen.
-
Det peger mod en fin åbning d. 2. januar: http://www.proinvestor.com/investornyt/584400/sampp-future-naeligsten-eacuten-procent-oppe-i-dag-den-31-12
-
-
Godt nytår til alle.
-
Godt nytår
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind